Abstract

Introduction: Visinin-like protein 1 (VILIP-1) is an established biomarker of neuronal injury. The levels of serum VILIP-1, neuron-specific enolase (NSE) and caveolin-1 (CAV-1) were measured to investigate potential of VILIP-1 as a biomarker for seizure-induced neuronal injury, and the correlation of VILIP-1 with severity of epilepsy and blood-brain barrier dysfunction were investigated.Materials and Methods: Patient with epilepsy from 14 to 70 years of age and age-, sex-matched healthy subjects were involved in this study. All blood sample of patients were collected within 3–72 h after the seizure. The severity of epilepsy and levels of serum VILIP-1, NSE and CAV-1 were measured. Accuracy of VILIP-1 and NSE was obtained from receiver operating curve analyses. Associations between VILIP-1 and severity of epilepsy, VILIP-1 and CAV-1 were investigated.Results: A total of 58 patients and 29 healthy control subjects were included in our study. The levels of serum VILIP-1, NSE, and CAV-1 in the patient group were significantly higher than those in the control group. VILIP-1 has higher and significant accuracy for assessing seizure-induced neuronal injury compared with NSE. VILIP-1 levels were positively associated with severity of epilepsy and CAV-1 in patients with epilepsy.Conclusions: VILIP-1 may be a better serum biomarker than NSE for assessing seizure-induced neuronal injury and even brain injury caused by various pathological condition. Further studies are required to explore the clinical contribution of VILIP-1 in diagnosis, treatment strategies and outcome assessments of epilepsy.

Highlights

  • IntroductionThe levels of serum Visinin-like protein 1 (VILIP-1), neuron-specific enolase (NSE) and caveolin-1 (CAV-1) were measured to investigate potential of VILIP-1 as a biomarker for seizure-induced neuronal injury, and the correlation of VILIP-1 with severity of epilepsy and blood-brain barrier dysfunction were investigated

  • Visinin-like protein 1 (VILIP-1) is an established biomarker of neuronal injury

  • Various biomarkers have been studied on seizure-induced neuronal injury, such as Neuron-specific enolase (NSE), S100 calcium binding protein B(S100B), Ubiquitin Carboxy-Terminal Hydrolase L1(UCH-L1), microtubule-associated protein 2(MAP2), tau protein, and so on [3,4,5,6,7,8]

Read more

Summary

Introduction

The levels of serum VILIP-1, neuron-specific enolase (NSE) and caveolin-1 (CAV-1) were measured to investigate potential of VILIP-1 as a biomarker for seizure-induced neuronal injury, and the correlation of VILIP-1 with severity of epilepsy and blood-brain barrier dysfunction were investigated. Previous studies have confirmed recurrent epileptic seizures may lead to neuronal injury in patients, that could induce subsequent irreversible neurologic structural changes, further development of epilepsy [2, 3]. Various biomarkers have been studied on seizure-induced neuronal injury, such as Neuron-specific enolase (NSE), S100 calcium binding protein B(S100B), Ubiquitin Carboxy-Terminal Hydrolase L1(UCH-L1), microtubule-associated protein 2(MAP2), tau protein, and so on [3,4,5,6,7,8]. NSE levels were associated with seizure severity [3, 10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call